Weekly Investment Analysts’ Ratings Updates for Praxis Precision Medicines (PRAX)

A number of firms have modified their ratings and price targets on shares of Praxis Precision Medicines (NASDAQ: PRAX) recently:

• 8/17/2026 – Praxis Precision Medicines had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $945.00 price target on the stock.
• 8/8/2026 – Praxis Precision Medicines was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/7/2026 – Praxis Precision Medicines had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $462.00 price target on the stock, up from $449.00.
• 8/7/2026 – Praxis Precision Medicines was given a new $514.00 price target by Robert W. Baird.
• 8/7/2026 – Praxis Precision Medicines had its “positive” rating reaffirmed by Wells Fargo & Company. They now have a $362.00 price target on the stock, up from $323.00.
• 8/6/2026 – Praxis Precision Medicines had its price target raised by Needham & Company LLC from $575.00 to $582.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $810.00 price target on the stock.
• 7/13/2026 – Praxis Precision Medicines had its “overweight” rating reaffirmed by Piper Sandler.
• 7/13/2026 – Praxis Precision Medicines is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $447.00 price target on the stock.
• 7/13/2026 – Praxis Precision Medicines is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $447.00 price target on the stock.
• 6/29/2026 – Praxis Precision Medicines had its price target raised by Needham & Company LLC from $537.00 to $575.00. They now have a “buy” rating on the stock.

Insider Activity at Praxis Precision Medicines

In other news, Director Jill Desimone sold 11,600 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the sale, the director owned 2,337 shares of the company’s stock, valued at $727,554.84. This trade represents a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is currently owned by corporate insiders.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.